Ascentage Pharma Group International (HKG:6855)

HKG:6855 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	2,470	1,261	1,094	1,492	1,744
Short-Term Investments	2.16	5.37	6.56	11.91	4.14
Cash & Short-Term Investments	2,472	1,267	1,100	1,504	1,748
Cash Growth	95.19%	15.10%	-26.84%	-13.95%	70.13%
Accounts Receivable	252.94	83.14	145.89	54.36	53.97
Other Receivables	48.2	15.93	17.65	7.13	22.48
Receivables	301.14	99.07	163.54	61.49	76.45
Inventory	28.62	6.6	16.17	9.45	3.93
Other Current Assets	142.17	101.91	64.08	61.41	56.93
Total Current Assets	2,944	1,474	1,344	1,636	1,885
Property, Plant & Equipment	829.06	905.56	957.07	648.72	844.37
Long-Term Investments	37.03	33.86	18.95	18.53	27.85
Goodwill	24.69	24.69	24.69	24.69	24.69
Other Intangible Assets	65.94	76	85.45	84.3	60.41
Long-Term Deferred Tax Assets	31.96	44.24	59.84	54.29	51.65
Long-Term Deferred Charges	29.85	30.53	-	-	-
Other Long-Term Assets	0.87	28.77	10.22	363.23	45.81
Total Assets	3,964	2,618	2,500	2,830	2,940

Liabilities

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	106.74	91.97	72.45	95.56	70.86
Accrued Expenses	216.38	153.33	125.68	120.65	75.32
Short-Term Debt	1,040	290	120	139.9	-
Current Portion of Long-Term Debt	175.2	479.62	486.65	370.41	39.8
Current Portion of Leases	7.28	9.44	9.76	8.08	9.65
Current Unearned Revenue	60.09	54.09	38.41	24.35	24.36
Other Current Liabilities	37.69	88.17	81.24	122.21	141.12
Total Current Liabilities	1,643	1,167	934.17	881.15	361.11
Long-Term Debt	742.33	868.64	1,166	1,265	1,027
Long-Term Leases	14.91	20.79	12.92	9.14	8.25
Long-Term Unearned Revenue	216.72	275.96	287.55	218.63	243.28
Long-Term Deferred Tax Liabilities	-	5.37	10.55	12.15	13.75
Other Long-Term Liabilities	12.03	6.27	18.3	35.33	52.34
Total Liabilities	2,629	2,344	2,430	2,422	1,705

Shareholders' Equity

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.26	0.21	0.2	0.18	0.18
Additional Paid-In Capital	8,917	6,545	5,951	5,393	5,342
Retained Earnings	-7,013	-5,771	-5,365	-4,439	-3,557
Treasury Stock	-2.96	-0.01	-21.35	-26.55	-0
Comprehensive Income & Other	-576.36	-510.59	-504.46	-518.51	-550.95
Total Common Equity	1,324	264.19	60.42	408.66	1,235
Minority Interest	9.75	9.97	10.22	-	-
Shareholders' Equity	1,334	274.16	70.63	408.66	1,235
Total Liabilities & Equity	3,964	2,618	2,500	2,830	2,940

Additional Metrics

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1,980	1,668	1,796	1,793	1,084
Net Cash (Debt)	492.53	-401.92	-695.21	-288.58	663.68
Net Cash Growth	-	-	-	-	33.34%
Net Cash Per Share	1.38	-1.33	-2.46	-1.09	2.61
Filing Date Shares Outstanding	370.67	312.37	290.05	259.91	257.61
Total Common Shares Outstanding	370.67	312.37	290.05	259.91	257.61
Working Capital	1,301	307.55	410.01	755.34	1,524
Book Value Per Share	3.57	0.85	0.21	1.57	4.79
Tangible Book Value	1,234	163.5	-49.72	299.66	1,150
Tangible Book Value Per Share	3.33	0.52	-0.17	1.15	4.46
Buildings	818.84	836.02	834.91	470.22	406.95
Machinery	186.58	183.34	179.87	155.21	60.98
Construction In Progress	2.11	7.29	12.65	39.49	362.86
Leasehold Improvements	60.73	44.24	29.22	7.74	8.14

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jul 25, 2026

Data Sources Report a data error